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ABSTRACT 
The normal cellular role of α-synuclein is of potential importance in understanding 
diseases in which an aggregated form of the protein has been implicated. A 
potential loss or change in the normal function of α-synuclein could play a role in 
the aetiology of diseases such as Parkinson’s disease. Recently, it has been 
suggested that α-synuclein could cause the enzymatic reduction of iron and a 
cellular increase in Fe(II) levels. Experiments were carried out to determine if such 
activity could be measured in vivo. Experiments with rats overexpressing human 
α-synuclein in nigral dopaminergic neurons demonstrated a correlation between 
α-synuclein expression and ferrireductase activity. Furthermore, studies on tissue 
from Parkinson’s disease patient brains showed a significant decrease in 
ferrireductase activity, possibly due to deposition of large amounts of inactive 
protein. Cellular studies suggest that increase ferrireductase activity results in 
increased levels of dopamine metabolites and increased sensitivity to the toxicity 
of DOPAL. These findings demonstrate that α-synuclein ferrireductase activity is 
present in vivo and its alteration may play a role in neuron loss in disease. 
INTRODUCTION 
Alpha-synuclein (α-syn) is a small protein (140 amino acid residues) predominantly 
found in the pre-synaptic cytosol of neurons (Maroteaux et al., 1988; Totterdell et 
al., 2004) that can also associate with the plasma membrane (Jao et al., 2004; Jao 
et al., 2008; Maroteaux and Scheller, 1991). It is one of a family of similar proteins 
which include beta-synuclein which is co-expressed with α-syn in neurons (Kahle 
et al., 2000). It is a monomeric protein, but may form tetramers under specific 
conditions (Bartels et al., 2011; Dettmer et al., 2013). It has been shown to bind 
metals such as copper and iron (Binolfi et al., 2006; Davies et al., 2010; Rasia et 
al., 2005), but its normal cellular activity remains to be fully determined. There is 
some evidence to suggest that its expression in dopaminergic neurons influences 
the packaging and trafficking of dopamine (Burre et al., 2010; Sidhu et al., 2004). 
There has also been the suggestion that it can alter the redox state of iron by 
reducing Fe(III) to Fe(II) (Davies et al., 2011). However, its most noted role is its 
association with a number of diseases that have been termed synucleinopathies 
(Goedert, 2001). 
The synucleinopathies include Multiple System Atrophy and Dementia with Lewy 
Bodies. However, the most well-known member of this family of diseases is 
Parkinson’s disease (PD) (Goedert, 2001). The nature of the possible causative 
role of α-syn in these diseases is unclear. However, deposits of α-syn in an 
aggregated, amyloidogenic form are present in Lewy Bodies which are 
characteristic of synucleinopathies (Spillantini et al., 1997). α-syn has also been 
found to be toxic both in vitro and in vivo (Winner et al., 2011; Wright et al., 2009). 
PD is characterized by extensive loss of dopaminergic neurons in the Substantia 
nigra in patient brains. It is unclear if aggregated α-syn plays a direct role in this 
neuronal loss, especially when α-syn-rich Lewy bodies are found in surviving 
neurons. Some inherited forms of PD are associated with point mutations in the α-
syn gene SNCA (Mullin and Schapira, 2015). 
The ferrireductase (FR) activity of α-syn was first demonstrated using recombinant 
human α-syn generated from bacteria (Davies et al., 2011). This was verified using 
human cells overexpressing α-syn which showed higher FR activity. The same 
cells showed elevated levels of Fe(II). As a potential enzyme α-syn showed simple 
kinetics with a Km and Vmax similar to other ferrireductases. The activity was found 
to be dependent on the presence of an electron donor such as NADH.  A more 
recent studies has provided a fuller picture of the kinetics of α-syn FR activity 
characterizing NADH and substrate dependence (McDowall et al., 2017). The 
study also identified the active isoform to be a membrane associated tetramer. The 
relation of this activity to synucleinopathy or dopamine metabolism was not 
determined. 
α-syn has been suggested to impact dopamine metabolism (Abeliovich et al., 
2000; Perez et al., 2002; Yu et al., 2005; Yu et al., 2004). There is evidence to 
suggest that level of expression of α-syn alters dopamine synthesis, but also 
dopamine entry into vesicles and its release (Gaugler et al., 2012; Lotharius and 
Brundin, 2002; Nemani et al., 2010). Additionally, dopamine and its metabolites 
have been suggested to interact with α-syn and alter its potential to aggregate 
(Follmer et al., 2015). A bi-product of dopamine breakdown in cells is 3,4-
Dihydroxyphenylacetaldehyde (DOPAL). DOPAL has been shown to be toxic to 
neurons and also able to increase the formation of α-syn aggregates (Goldstein et 
al., 2012; Jinsmaa et al., 2016). The level of DOPAL is increased in PD patients 
(Burke, 2003) and it is toxic in vivo (Burke et al., 2003). 
In the current investigation we sought to further our investigations of α-syn FR 
activity and its relevance to in vivo models and Parkinson’s disease. We also 
sought to determine if increase α-syn FR activity would impact dopamine 
metabolism and the toxicity of DOPAL. Our results confirm that α-syn is a 
ferrireductase in vivo and that levels of FR activity are altered in the striatum of PD 
patients. Ferrireductase activity rather than simply α-syn expression alters 
dopamine synthesis and breakdown and increase cellular sensitivity to DOPAL 
toxicity. 
MATERIALS AND METHODS 
Reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise 
stated. 
Viral vector production and titration 
Serotype 6 adeno-associated viral (AAV6) vectors were produced and titrated as 
previously described (Gaugler et al., 2012). The number of transducing units (TU) 
was determined by infecting HEK293T cells. The number of S1-nuclease resistant 
vector genome copies was measured by real-time PCR at 48 hrs post-infection. 
The AAV6-α-syn vector encodes expression of full-length wild-type human α-syn 
under the control of the constitutive mouse pgk-1 promoter. The control non-coding 
AAV6 vector contains a similar empty expression cassette. The titres of the vector 
suspensions were 7.9E10 TU/ml for the AAV6-α-syn vector and 2.1E10 TU/ml for 
the non-coding AAV6 vector. 
Animal experiments 
All procedures were performed in accordance with Swiss legislation and the 
European Community Council directive (86/609/EEC) for the care and use of 
laboratory animals. Female adult Sprague-Dawley rats (Charles River 
Laboratories, France), weighing 180-200g, were housed in a 12h light-dark cycle, 
with ad libitum access to water and food. Rats were injected with AAV6 vectors in 
the right substantia nigra. For both AAV6-α-syn and non-coding AAV6 vectors, the 
total injected dose for each animal was 2.8E7 TU in a volume of 2 µl. The general 
procedure for vector injection was as previously described (Gaugler et al., 2012). 
We used the following stereotaxic coordinates: 5.2 mm anterior and 1.9 mm lateral 
to bregma point, 7.9 mm ventral from the skull surface. The injected rats were 
culled at both one month and three months after injection. For biochemical 
analysis, fresh tissue was obtained for both substantia nigra and striatum from 
each brain hemisphere separately, after one and three months. For 
immunohistochemistry, the animals were perfused three months after vector 
injection with 4% paraformaldehyde, as described previously (Gaugler et al., 
2012).  
Immunohistochemistry and quantitative analysis 
The primary antibodies were anti-tyrosine hydroxylase (TH) (AB152 Chemicon, 
CA, 1:500) and anti-α-syn antibody (AB5334P Chemicon, 1:800). For bright-field 
microscopy analysis, TH immunohistochemistry and 3,3'-diaminobenzidine 
solution (DAB) revelation were performed on nigral and striatal slices, as 
previously described (Gaugler et al, 2012). The percentage loss of TH-positive 
neuronal cell bodies was determined by stereological counting as described in 
(Gaugler et al., 2012). Striatal dopaminergic innervation was quantified by 
measuring the optical density (OD) of TH-immunoreactive terminals in one in six 
sections throughout the entire striatum. Sections were scanned using Nikon Super 
Coolscan 4000 and the OD was analyzed using the free ImageJ software. The OD 
was measured as the integrated density of grey values of pixels with correction for 
non-specific background. Results normalised for surface area were expressed as 
a percentage of the non-injected side. All analyses were performed in a blinded 
fashion.
For immunofluorescence, slices were blocked in 10% normal donkey serum 
(Jackson) and 0.1% Triton X-100 in PBS. Anti-α-syn antibody was incubated 
overnight at 4°C. For revelation, we used a secondary antibody conjugated to 
Alexa Fluor 546 dye (Molecular Probes), incubated for 2 hrs at room temperature. 
Sections were mounted on glass slides using MOWIOL. 
Brain Tissue Samples 
Patient tissue samples were obtained from the London Neurodegenerative 
Diseases Brain Bank. The ethical permission to obtain the tissues was supplied by 
the London City and East NRES Committee (08/H0704/128). 10-20 samples of PD 
patient substantia nigra and striatum were obtained along with 20 samples of non-
PD controls that were matched for both age of the patient and post-mortem delay 
in processing. Statistical analysis was carried out using Analysis of Variance 
(ANCOVA) and F and p values determined. 
Cell culture 
SH-SY5Y (human neuroblastoma) cells were cultured in DMEM (Lonza) 
supplemented with 10% FBS, and pen/strep.  Cells were maintained at 37oC and 
5% CO2 in a humidified incubator. The neuronal status of SH-SY5Y cells was 
monitored by RT-PCR with primers for tyrosine hydroxylase (TH), dopamine 
transporter (DAT) and vesicle mono-amine transporter 2 (VMAT2). Cells were 
used within 20 passages of the original vial.  
Stable cell lines overexpressing either wild-type or mutant human α-syn were as 
previously described (Wang et al., 2010). The cell lines were established from SH-
SY5Y cells via transfection using Fugene (Promega). All proteins were expressed 
from pCDNA3.1(+). The resulting cells were then selected by growth in medium 
contain G418 at 800 µg/ml for at least two weeks. The lines were screened by 
western blot to confirm expression of the protein of interest.  The mutants included 
in this study were a deletion of amino acid residues 2-9 of the α-syn sequence (Δ2-
9) and a deletion of amino acid residues 71-82 of the α-syn sequence (ΔNAC).
Additionally, cell lines for human beta-synuclein (β-syn) (Wang et al., 2010) and 
the human ferrireductase, Steap-3 (six-transmembrane epithelial antigen of the 
prostate 3) metalloreductase (Sendamarai et al., 2008) were also included. Steap-
3 was cloned by isolation of mRNA from SH-SY5Y and reverse transcription of the 
open reading frame using specific primers before cloning into pCDNA3.1(+). 
Western Blotting
 Cells were lysed in 0.5% Igepal CA-630 and ‘complete’ protease inhibitor 
cocktail (Roche), sonicated 3 x 3 seconds on ice, and centrifuged 10 000 xg for 3 
minutes to remove insoluble membranes. Brain samples were prepared as 
described for the ferrireductase assay.  Protein concentration was determined with 
a Bradford protein assay (Bio-Rad), according to the manufacturer’s instructions. 
Protein concentrations were normalized and boiled for 5 minutes with 1 x Laemmli 
SDS-PAGE buffer. Samples were loaded into a 12% acrylamide SDS-PAGE gel, 
with a buffer of Tris (250 mM) + Glycine (1.92 M) + SDS (0.1% w/v), run at 250V 
for 45 minutes. Separated proteins were transferred to a PVDF membrane by a 
semi-dry transfer apparatus, run at 25 V for 1.3 hours. Membranes were blocked 
in 5% w/v non-fat milk powder in TBS-T for 30 minutes, incubated with primary 
antibody for 1-2 hours, and washed 3 x 5 minutes in TBS-T. Membranes were 
blocked again and incubated with horseradish peroxidase-conjugated secondary 
antibody for 1 hour. A further 3 x 10 minute washes were performed, and the 
membranes developed with Luminata Crescendo or Luminata Forte ECL substrate 
(Thermo Scientific), and imaged with a Fusion SL CCD imaging system (Vilber 
Lourmat). 
Rabbit monoclonal anti-α-synuclein (MJFR1, Abcam, immunogen human α-
synuclein 1-150) was used for human α-synuclein detection at a dilution of 1:4000. 
Mouse monoclonal anti-α-synuclein (610787, BD Biosciences, immunogen rat α-
synuclein 15-123) was used for rat α-synuclein detection at a dilution of 1:2000. 
Mouse monoclonal anti-α-tubulin (T5186, Sigma, immunogen acetylated tubulin
from Strongylocentrotus purpuratus sperm axonemes) was used at a dilution of 
1:10,000. Mouse monoclonal, anti-dopamine transporter (AB2231, Millipore) was 
used at 1:1000 dilution.  
Ferrireductase Assay 
The ferrireductase assay was based upon the reaction of ferrozine with Fe(II) in 
the presence of NADH and was similar to the previous method(Davies et al., 2011). 
The reaction contained 20 mM MOPS pH 7.0 as the buffer and included 500 µM 
NADH, 500 µM ferrozine and varying concentration of protein extract depending 
upon the material to be assayed. The reaction was initiated by the addition of Ferric 
ammonium citrate prepared as a stock concentration of 25 mM. The amount added 
depended on the concentration required for the reaction. The final volume of the 
reaction was either 250 µL or 1.0 mL depending of the instrument used to measure 
the kinetics of the reaction. The assay was carried out by monitoring absorbance 
at 562 nm for at least 30 min. Experiments were performed in 1 mL quartz cuvettes 
in a Libra S22 spectrophotometer (Biochrom) or in 250 µL in 96 well plates using 
a Fluorostar Omega plate reader (BMG). Brain samples were prepared in 0.5% 
Igepal in distilled water and sonicated, Samples from cultured cells were prepared 
by scraping a confluent T75 flask of cells into 0.5 mL of distilled water. The 
membranous fraction was collected by centrifugation and washed several times 
with PBS. The resulting pellet was then resuspended with PBS containing 0.5% 
Igepal. After 30 minutes on ice the protein extract was cleared of debris by 
centrifugation and the supernatant collected. Protein content was determined 
using the Biorad protein assay kit using a BSA standard curve. Brain samples were 
prepared by sonicating the tissue into PBS with 0.5 % Igepal. 
Dopamine Assay 
Dopamine was detected in the extracts of SH-SY5Y cells overexpressing α-syn or 
various mutants of α-syn, Steap-3 and β-syn using a commercial ELISA kit 
(Abnova) following the manufacturer’s instruction. 
Electrochemical Detection 
Lysates from different SH-SY5Y cell lines were prepared by scraping of confluent 
T75 flasks into a mobile phase (see below). The samples were sonicated and 
cleared debris by centrifugation before being stored at -20oC prior to analysis. 
Once defrosted the samples were vortexed for 30 s to ensure homogeneity.  A 100 
µL aliquot of the resulting cell lysates was diluted with an additional 100 µL of 
mobile phase and vortexed for 30 s.  A 20 µL aliquot was then examined by liquid 
chromatography with electrochemical detection (LC-EC). Samples were examined 
using C18 reverse-phase column (Symmetry Shield, RP18, 5 µm, 250 mm x 4.6 
mm, Waters) at room temperature.  A mobile phase of 10% acetonitrile, 90% 50 
mM phosphate buffer pH 3.0 containing 20 mM octane sulfonic acid was used at 
a flow rate of 1.0 mL/min.  Amperometric detection was carried out using an 
applied potential of +0.5 V (ESA Coulochem II).  Quantification was undertaken by 
external calibration for dopamine, 3,4-Dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA). 
MTT assay 
For toxicity experiments, cells were plated in 24 well plates (Gibco) and grown 
overnight. They were then treated for 48 hours with varying concentrations of 
DOPAL (Cayman Chemical Company) in 10 µl of methanol. Control wells were 
treated with 10 µl of methanol alone. After 48 hours the viability of the cultures was 
assessed with an MTT assay. The MTT (3, [4,5 dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide) reagent was resuspended to 2.5 mg/ml. Treatments 
were removed and 50 µl of MTT per well was incubated for 30 minutes. After 
removal of MTT, deposits were solubilised in DMSO. Readings were taken at 570 
nm using FLUOstar Omega (BMG Labtech). Each treatment was conducted in 
triplicate, averaged, and then represented as percentage of the control (methanol 
alone). Each experiment was repeated 4 times. Statistical analyses were 
conducted using a two-tailed Student’s t test, statistical significance at p-value of 
< 0.05. Data are expressed as the mean ± standard error (S.E.). 
Recombinant Protein and Aggregates 
Human recombinant α-syn was generated as previously described (Davies et al., 
2010). Briefly, human α-syn was overexpressed in bacteria and purified from the 
lysed bacteria. A 15% ammonium sulphate precipitation was performed to 
separate α-syn from the majority of bacterial proteins. Further purification was 
received using anion exchange using sepharose Q hi-trap column (GE Healthcare) 
on an ACTA purification system (GE Healthcare). The purified protein was filtered 
through a 30 kD cut off membrane (Millipore) before dialysis and further 
concentration as needed. Protein aggregation was achieved by rapid shaking at 
1200 r.p.m. for seven days at 37oC as previously described (Wright et al., 2009). 
Success of the aggregation process was checked using a ThT (thioflavin T) assay 
as previously described (Wright et al., 2009). 
RESULTS 
α-syn FR activity in the rodent substantia nigra and striatum 
Previous work has demonstrated that α-syn can act as a FR in both cell models 
and with purified recombinant protein (Davies et al., 2011). Therefore, it is 
important to establish that α-syn also has FR activity in vivo. A previously 
established model of α-syn overexpression was utilised to confirm α-syn FR 
activity in vivo (Gaugler et al., 2012). In this model, rats were unilaterally injected 
with an AAV6 vector to induce overexpression of human α-syn within the 
nigrostriatal system. Figure 1 shows analysis of rats that were injected either with 
the AAV6-α-syn vector or with non-coding AAV6 control vector. Analysis was 
carried out three months after the injection. Coronal sections through the midbrain 
and striatum were taken and stained to detect tyrosine hydroxylase (TH) and α-
syn. After three months, there was a marked reduction (-46.3±7.4%) in the number 
of TH-positive neurons for the AAV6-α-syn rats when comparing the substantia 
nigra pars compacta in the injected and non-injected sides (Figure 1A & B). No 
such difference was observed for the rats injected with the control non-coding 
AAV6 vector (-1.5±6.3%). In the striatum, there was only a 22.5±4.9% loss of TH 
immunoreactivity in the AAV6-α-syn rats, which was not statistically different when 
compared to the rats injected with the non-coding AAV6 (Figure 1C & D). It is 
therefore possible that compensatory changes reduced the loss of striatal TH-
positive innervation. To verify transgene expression, similar sections were stained 
to detect α-syn in both the substantia nigra and striatum. As expected, fluorescent 
immunostainings showed dramatically higher levels of α-syn expression when 
compared to the non-injected hemisphere (Figure 1E). 
Tissues from rats that had also been injected with the same AAV6 virus were 
analysed for both FR activity and levels of α-syn and TH protein. Samples were 
collected from rats both one month and three months after injection with the AAV6-
α-syn vector. Samples were collected from both the substantia nigra and the 
striatum of both the injected and non-injected sides. Additionally, similar tissue was 
collected at a one month time point from rats injected with the non-coding AAV6 
control. The initial rate of the FR reaction was determined for each sample using 
0.7 mg/ml of protein extract and 500 µM Fe(III). Six samples for each condition 
were analysed and the averaged data are shown in Figure 2A. The samples from 
the AAV6-α-syn injected rats showed a significantly higher initial rate in the FR 
assay (both striatum and substantia nigra). No other condition showed a significant 
increase in FR activity. The expression of α-syn relative to the levels of dopamine 
transporter (DAT) were used to verify that only the AAV6-α-syn injected samples 
showed increased α-syn levels (Figure 2B). These results demonstrate that 
increased α-syn levels result in increased FR activity in vivo. 
Cell loss in the substantia nigra was demonstrated three months after injection of 
AAV6-α-syn (see above). We therefore compared the FR activity levels in AAV6-
α-syn injected rat brain regions from three months after injection to those observed 
at 1 month, (Figure 3A). At one month, both striatum and substantia nigra samples 
showed elevated FR activity in the AAV6-α-syn injected side compared to the 
control side. However at three months the elevation was lost in the substantia 
nigra. There was no significant change in the striatum at three months compared 
to one month. The same samples were analysed for the expression of both α-syn 
and DAT (Figure 3B &C). There was a clear decline in the expression of both α-
syn and DAT for substantia nigra samples between one month and three months 
and marked reduction in the ratio of the two indicating a loss of α-syn relative to 
the amount of DAT. There was no observed change in the levels of α-syn and DAT 
in the striatum. Overall, these results suggest that the level of FR activity observed 
in the rat brain tissue samples was proportional to the amount of α-syn expressed. 
This supports the suggestion that α-syn acts as a ferrireductase in vivo. 
α-syn FR activity in PD 
We obtained samples of substantia nigra and striatum from patients with PD and 
aged matched controls. We analysed the samples for FR activity, α-syn protein 
levels and DAT protein levels (Figure 4). The initial rate of FR activity was 
determined using the ferrozine assay. DAT and α-syn levels were assayed by 
western blot. To ensure the western blot data was equivalent a standard was 
included on all blots so that direct comparison could be made between all samples. 
Between 10 and 20 samples were analysed per group. The FR activity for the 
samples was compared to the level of α-syn expression and any correlation 
observed. In general, control samples showed increased activity in proportion to 
the level of α-syn expression. However, PD samples did not show the same trend 
and higher expression was more closely related to a decreased or unaltered 
activity. When comparing the PD and control samples, the striatum samples 
showed a significant decrease in FR activity relative to α-syn expression when 
analysed by ANOVA (F=4.94, p=0.033). However, there was no significant 
difference between the substantia nigra samples when comparing PD and control 
(F=1.32, p=0.262). We also looked at the level of α-syn expression relative to the 
level of DAT for each sample (Figure 4).  The distribution was fairly equivalent for 
PD and control striatum samples. However, PD substantia nigra samples were 
more clustered with low α-syn and low FR activity relative to the controls. These 
findings demonstrate that there is a decrease in FR activity in PD patient striatum. 
α-syn aggregates have no FR activity
We previously demonstrated that recombinant α-syn has FR activity (Davies et al., 
2011). The changes in activity identified in PD brains striatum increased levels of 
α-syn expression does not lead to increased activity. We therefore sought to 
determine if aggregated α-syn has altered FR activity. We generated aggregates 
of α-syn as previously described (Wright et al., 2009) using a rapid shaking method 
over seven days. Aggregation was assessed using the standard ThT method. 
Using the ferrireductase assay we could measure FR activity in non-aggregated 
α-syn but not in aggregated protein (Figure 5). These results suggest that when α-
syn is aggregated it loses its FR activity. Therefore the decreased levels of FR 
activity measured in samples with high α-syn content could be due to aggregation. 
FR activity and the levels of dopamine and it metabolites in cells 
There has been significant discussion of the potential of α-syn to alter the secretion 
and possible formation of dopamine and it metabolic break down products. We 
were therefore keen to do determine if FR activity of α-syn could influence 
dopamine levels and its metabolism. We previously generated a number of cell 
lines using SH-SY5Y cells that express either wild-type α-syn, β-syn or mutants of 
α-syn. We included in this study two mutants of α-syn Δ2-9 (missing the N-
terminus) and ΔNAC (missing the NAC region, amino acid residues 71-82). Lastly, 
we included another known ferrireductase, Steap-3. Protein extracts were 
prepared from the cells and used to assess FR activity (Figure 6A). Clear 
differences in activity were seen with both α-syn and Steap-3 showing the highest 
activity. The two mutants lacking specific domains showed greatly reduced activity 
indicating the mutations allowed expression of α-syn with diminished FR activity. 
In comparison extracts from cells expressing β-syn showed no FR activity. We 
used a commercial kit to measure the levels of dopamine in extracts from these 
cell lines. Despite the expression of these different proteins at high levels, none of 
the cell lines showed any significant difference to a cell line transfected with the 
empty vector (Figure 6B).  These results suggest that neither α-syn nor increased 
FR activity alters dopamine levels. 
We then used HPLC with electrochemical detection to assess if the same cell lines 
showed alterations in the breakdown products of dopamine.  Within the cell 
dopamine that is free in the cytosol is rapidly metabolized to DOPAL (3,4-
Dihydroxyphenylacetaldehyde) by mono-amine oxidase and then further 
metabolized to DOPAC (3,4-Dihydroxyphenylacetic acid) by aldehyde 
dehydrogenase. Further degradation to HVA (homovanilic acid) is dependent upon 
encountering catechol-O-methyl transferase which has low cell expression. 
Therefore, we assessed DOPAC and HVA levels for the cell lines (Table 1). As 
can be seen, the levels of the two metabolites were similarly increased in both α-
syn and Steap-3. However, neither β-syn nor the mutants of α-syn with reduced 
activity showed any change in these metabolites. We also measured dopamine 
with HPLC and the result confirmed the findings from the commercial assay that 
α-syn overexpression does not alter it levels in cells (data not shown). These data 
suggests that FR activity of α-syn may cause an increase in the rate of degradation 
of dopamine. 
α-syn FR activity increases cellular sensitivity to DOPAL toxicity 
Given that α-syn expression altered the levels of dopamine breakdown products 
we wished to know if this could have an impact on cellular survival. DOPAL is 
believed to be toxic to cells if it accumulates at high levels. Therefore we used cell 
survival assays to assess DOPAL was differentially toxic to cells overexpress α-
syn.  Cells overexpressing either α-syn or the known FR Steap-3 were compared 
to cells transfected with the empty vector. After 48 hours of treatment, the cells 
were assessed with an MTT assay to determine relative viability. A significant 
difference in viability was seen for both α-syn and Steap-3 expressing cell lines for 
2 µM DOPAL and above when compared to the control cell line (Figure 7A). This 
suggests that FR activity makes cells more vulnerable to the toxicity of DOPAL. 
We also tested the toxicity of DOPAL on other cell lines. Cell lines expressing β-
syn or the two α-syn mutant Δ2-9 and ΔNAC showed significantly reduced levels 
of DOPAL toxicity when compared the α-syn cell line (Figure 7B). As these cell 
lines have much less FR activity it is likely that the impact of α-syn on DOPAL 
toxicity is due to its FR activity. 
DISCUSSION 
The identification of a potential enzymatic function for α-syn necessitates 
verification that this activity is present in vivo. The first aim of the research present 
here was to determine if increased FR activity can be detected with increased α-
syn expression in a rodent model. Rats unilaterally injected with the AAV6-α-syn 
vector in the substantia nigra showed increased expression of human α-syn. Both 
in the substantia nigra and in the striatum, FR activity was increased only when 
there was increased α-syn expression. Secondly, neuronal death in the substantia 
nigra where there was initially increased expression resulted in loss of both α-syn 
expression and FR activity. Additionally, in human brain tissue (non PD) the level 
of FR activity correlated with increased α-syn expression. This evidence strongly 
supports that α-syn is an FR in vivo. These findings need to be assessed along-
side previous studies where purified, recombinant α-syn showed FR activity in 
isolation from other cellular components (Davies et al., 2011; McDowall et al., 
2017). Without this evidence it could be argued that α-syn expression could alter 
the behaviour of other iron- reducing systems without being directly involved. 
Additionally, we have shown previously that the FR activity is heat sensitive, 
membrane associated and can be selectively immunoprecipitated from the 
membranes of dopaminergic cells, fully accounting for any increase caused by 
overexpression of the protein (McDowall et al., 2017). This implies that the 
increase FR activity we observe in these studies is entirely due to α-syn. 
Rodent models have been particularly important in assessing the impact of α-syn 
expression on neuronal survival. High α-syn expression has been shown to lead 
to cell death (Gaugler et al., 2012). The cell death occurred in the substantia nigra. 
In this study we looked at the striatum in parallel as this is the principal area of 
innervation by dopaminergic neurons of the substantia nigra. Our analysis did not 
observe any changes in FR activity in the striatum following neuronal loss in the 
substantia nigra. Levels of DAT, α-syn and FR activity all remained similar between 
the one and three month time points in this brain region. This is likely to be due to 
the remaining neuronal population of the substantia nigra expanding axonal 
branching to encompass the additional targets. 
The potential impact of FR activity from α-syn on the disease state is clearly very 
important. However, assessment of an enzymatic activity within post mortem 
tissue is subject to potential loss of activity due to the age and storage conditions 
of the material assessed.  The impact of this on our results is difficult to assess. 
However, controls samples showed a linear relation between α-syn levels and FR 
activity for both the substantia nigra and striatum samples which is supportive that 
this approach has validity. More importantly, there was a significant difference in 
the striatum in regards of FR. Samples with higher α-syn levels showed lower 
activity. This trend was evident in the substantia nigra samples as well but did not 
reach significance. α-syn is an amyloidogenic protein and its aggregation in 
disease is a hallmark of PD. We verified that aggregated α-syn has no FR activity. 
It is likely that PD samples with high α-syn content probably have significant 
amounts of aggregated α-syn. Therefore the difference observed between control 
and PD samples is likely to be due to α-syn aggregation and subsequent loss of 
activity. 
A loss of activity relative to the amount of α-syn present does not indicate a 
possible mechanism of dopaminergic neuron death. Lewy bodies (which contain 
aggregates of α-syn) are usually intracellular and therefore present in viable cells 
or their axons. Also, the significant change in FR/ α-syn was in the striatum which 
is more likely to be activity associated with axonal or terminal α-syn content. In the 
rodent model there was a loss of expression and a loss of FR activity in the 
substantia nigra which is more likely to be due to neuron loss. What is unclear is 
whether the neuronal loss is related in any way to the increased FR activity. In the 
rodent model, which involved viral delivery of an α-syn expression system, there 
is no evidence for the extent of aggregation of the protein, nor the nature of the 
cells overexpressing α-syn. However, there is a distinct possibility that elevated 
FR activity (and increased Fe(II)) would constitute an additional toxic load that may 
result in cell death. 
It is important to consider the difference between the observations in the rat model 
and the changes seen in PD. Both models show a change in the levels of α-syn in 
the substantia nigra, but an actual significant reduction in FR activity was seen in 
the rat model only. In the case of the rat model the α-syn present is a result of 
transgenic overexpression and may not be expressed solely in dopaminergic 
neurons (which is not the case in the striatum, where it would have been 
transported along axons). Also, assessment in PD brain tissue is fundamentally 
more challenging because of the age and state of the material being not ideal for 
the preservation of enzymatic activity. Thus variability unrelated to changes in α-
syn aggregation and FR activity might mask a result that would have been 
equivalent to that observed in the striatum (i.e. reduced activity relative to the 
amount of protein present). It should be noted that aggregation of α-syn is often 
relative to its concentration, thus in the rat model significant amounts of 
aggregation may have been present (due to overexpression) at both one and three 
months and that change in the FR activity is not related to a change in the nature 
of the protein but simply as a result of the loss of cells expressing α-syn. 
We turned to a cell model to investigate whether increased FR activity has 
consequences for neuronal viability. One of the most obvious sources of toxicity 
for dopaminergic cells would be accumulation of a dopamine metabolite that is 
toxic. There is good evidence that DOPAL can be toxic and it is a product of 
dopamine breakdown by mono-amine oxidase. We assessed the levels of 
dopamine and various metabolites in SH-SY5Y cells and found an increase in 
DOPAC, a further breakdown product of DOPAL (via aldehyde dehydrogenase) 
where there was increased FR activity. This change suggests that FR activity (or 
increased Fe(II)) accelerates dopamine breakdown or causes accumulation of 
metabolites in cells. Unlike other reports have suggested (Lotharius et al., 2002; 
Perez et al., 2002), we did not see any change in dopamine itself, as a result of α-
syn overexpression, which indicates the changes in DOPAC are a change in the 
rate of breakdown and not just a result of their being more dopamine in cells. Also, 
unlike other reports, we were not able to detect DOPAL due to its significant 
insolubility in the HPLC mobile phase. This is in contrast to other who have report 
DOPAL measurements with HPLC-ECD (Wey et al., 2012). However, given the 
increase in both DOPAC and HVA, it is reasonable to conclude that all breakdown 
species are increased. 
Cell lines facilitate molecular studies but their continued division masks any 
potential changes in viability due to toxic molecules. We therefore treated SH-
SY5Y cells with exogenous DOPAL to determine if FR activity altered the cellular 
response to its toxicity. FR activity increased DOPAL toxicity significantly. These 
findings provide a potential mechanism by which high levels of α-syn FR activity 
could specifically induce cell death in dopaminergic neurons. If such a mechanism 
was active in the substantia nigra it would imply that altered FR activity would 
contribute to cell death. Alternatively, increased Fe(II) levels could be toxic without 
any involvement of DOPAL. While either is possible the potential role of DOPAL is 
more convenient as it would be a more unique target for therapeutic intervention 
than the ubiquitous Fe(II). Also, it has been suggested that Fe(II) can increase the 
rate of DOPAL mediated α-syn aggregation (Jinsmaa et al., 2014). 
The fundamental requirement for α-syn FR activity to play a role in altering 
neuronal viability in PD is that its expression, and subsequently FR activity, is 
increased during disease progression. The formation of aggregated α-syn is 
believe to be largely a result of increased expression and subsequent molecular 
crowding (Munishkina et al., 2008). However, it is unclear if there is genuinely an 
increase in α-syn expression during early PD. In our study, there was clearly a 
distribution of expression levels in human tissue. PD substantia nigra showed a 
trend to lower expression. However, such material is clearly from after significant 
cell loss has occurred and in general higher activity in PD patients correlated with 
lower FR activity. There is strong support for the idea from inherited PD particularly 
in regards the PARK4 locus which is a duplication of the SNCA gene and results 
in significantly higher expression of α-syn (Itokawa et al., 2013). There is other 
evidence to support that PD patients have elevated levels of α-syn which includes 
studies of fibroblasts (Hoepken et al., 2008) and also from micro-analysis of mRNA 
levels in surviving PD patient dopaminergic neurons (Grundemann et al., 2008) or 
generally in the mid-brain (Chiba-Falek et al., 2006). However, there are other 
reports that suggest there might be no increase, but these are largely based on 
looking at CSF or other tissues (Tokuda et al., 2006), (Wirdefeldt et al., 2001). 
FR activity is clearly an essential activity for cells that require replenishment of 
Fe(II) for cellular metabolism. Clearly, there is a consequence for cells of excess 
Fe(II) because of its potential to initiate damage through radical generation (Fenton 
chemistry) but whether overexpression of a ferrireductase could result in toxic 
levels of Fe(II) has had little consideration. We could find no cases in the literature 
of mutant ferrireductases associated with cell loss. However, changes in iron are 
well known to be associated with PD (Dexter et al., 1991; Dexter et al., 1990; 
Dexter et al., 1987; Dexter et al., 1989) and until this point there has been no clear 
explanation for this. Interestingly, a recent study of inherited PD associated with 
mutations in RAB39B resulted in reduced α-syn levels but increased iron 
accumulation (Wilson et al., 2014). The study was carried out in post-mortem 
tissue in which high α-syn neurons may have been lost. However, the correlation 
with PD and altered iron metabolism remains.  
In summary, our findings verify that α-syn has FR activity in vivo and that FR 
activity correlated with α-syn expression is altered in PD. We also provide a 
possible mechanism by which increase FR activity in the presence of DOPAL could 
cause neuronal loss. Targeting excess generation of Fe(II) in PD patients could be 
a potential therapeutic option for the development of novel PD treatments. 
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FIGURE LEGENDS 
Figure 1 AAV6-α-syn injection in the rat substantia nigra leads to 
neurodegeneration 
Rats were unilaterally injected in the substantia nigra either with a control non-
coding AAV6 vector or with the AAV6-α-syn vector for overexpression of human 
α-syn. Degeneration of the nigrostriatal system was analysed at three months post-
injection. A Representative sections of the ventral midbrain showing TH-positive 
neurons in the substantia nigra, comparing the injected and non-injected 
hemispheres near the site of injection. Note the loss of TH-positive neurons (*) in 
the substantia nigra injected with the AAV6-α-syn vector. B Stereological analysis 
of the percentage loss of TH-positive nigral cell bodies, comparing the injected with 
the non-injected substantia pars compacta in each animal. Statistical analysis: 
Student’s t test, n=6 in each group; ***p<0.001. C Representative sections of the 
striatum showing TH-positive innervation in rats injected either with the non-coding 
or with the AAV6-α-syn vector. * indicates the injected side. D Quantification of the 
percentage loss of dopaminergic axons in the striatum by comparing optical 
density of TH immunostaining in the injected and non-injected hemispheres. 
Statistical analysis: Student’s t test, n=6 (α-syn) and n=7 (non-coding); ns: not 
significant. E Representative pictures of α-syn fluorescent immunostainings 
showing human α-syn overexpression in the rat substantia nigra and striatum in 
the injected hemisphere. Scale bars: 100 µm. 
Figure 2 α-syn FR activity in AAV6-α-syn injected rats at one month
Protein extracts were prepared from the substantia nigra (SN) and the striatum 
(STR) from rats that had either been injected with the AAV6-α-syn vector (Exp) or 
a non-coding sham vector without the α-syn ORF (Sham). Samples analysed were 
from both the injected side and the contralateral non-injected side (control). The 
extracts were used to measure FR activity using the ferrozine assay (A) or western 
blots to detect α-syn and DAT (B). The data in A is the average of six different 
animals per treatment with s.e.m. * Indicates values significantly different to control 
and sham groups (p < 0.05, Student’s t test).
Figure 3 α-syn FR activity in AAV6-α-syn injected rats after 3 months
A Protein extract were prepared from the substantia nigra (SN) and the striatum 
(STR) from rats that had either been injected with the AAV6-α-syn virus. Extracts 
were also prepared from the substantia nigra (CSN) and striatum (CSTR). The 
samples had been collected either one month or three months after injection. The 
samples were analysed for FR activity using the ferrozine assay. There were nine 
animals used the one month time point and five for the three month time point. 
Shown are mean and s.e.m. of the measured initial rate for the different treatments. 
* Indicates a significant difference between injected and the non-injected side. # 
Indicates a significant difference between one month and three months. 
B & C. Western blot was used to analyse the expression of α-syn and DAT in the 
samples of rat brain. The level of expression was compared using densitormetry 
and the ratio of α-syn to DAT determine for each sample. At the one month time 
period the ratio of α-syn to DAT was highest for the substantia nigra (SN). When 
comparing the ratio at three months to one month there was a significant reduction 
in the value (p < 0.05, Student’s t test) indicating a loss of α-syn relative to the 
levels of DAT. The ratio of α-syn to DAT for the striatum (STR) showed no 
significant change between one month and three months. 
Figure 4 FR Activity in PD brain samples 
Samples from both striatum (STR) and the substantia nigra (SN) from both PD 
patients and controls were obtained and protein extracts prepared. The FR activity 
was measured using the ferrozine assay. Levels of DAT and α-syn were also 
determined using western blot. A standard was used across all western blots to 
allow comparison between samples. Densitometric analysis was carried out on 
western blots and normalised to the internal standard. An example of a western 
blot for both α-syn and DAT is shown at the bottom. The levels of FR activity were 
compared to levels of α-syn for each sample and plotted (upper two panels). A 
trend-line was fitted to the four sets and statistical analysis was carried out by 
ANCOVA. The data for the STR showed a significant difference between the 
control and PD groups but this was not observed in the SN data.  In addition, the 
levels of α-syn to DAT was also plotted for each sample (middle panels). The 
relation of α-syn to DAT is uniform when comparing the STR groups but in the SN 
groups the PD samples are largely grouped showing low FR activity and α-syn 
levels when compared to controls. 
Figure 5 FR activity of aggregated recombinant α-syn 
Recombinant human α-syn was generated by bacterial expression and purified 
using ion affinity chromatography. Aggregation was induced by shaking at 1200 
r.p.m. at 37oC for seven days. A The extent of aggregation was determined using 
a thioflavin T (ThT) assay. Fluorescence was measured at 482 nm with 440 nm 
excitation. The values were plotted on log scale. Aggregated samples were 
significantly more fluorescent than controls (n=6). B Samples of the aggregated 
protein were added to FR ferrozine assay along-side non aggregated controls. The 
assay was run standardly for 30 minutes but an example is shown for a much 
longer assay. The aggregated sample was mixed every 5 minutes. Measurements 
were recorded every 40 seconds. 
Figure 6 FR and dopamine levels in SH-SY5Y cells 
A The level of FR activity was determined in several SH-SY5Y cell lines that had 
been stably transfected to overexpress α-syn, two mutants of α-syn (Δ2-9 and 
ΔNAC), β-syn or Steap-3. A cell line transfected with the empty vector (pCDNA) 
was included as a control. Protein extracts were prepared from the cells and the 
protein content determined. The initial rate for each cell line in the FR ferrozine 
assay using 500 µM Fe(III) and equivalent amounts of protein was determined. 
Shown are the mean and s.e.m. for n=4 experiments. α-syn, Δ2-9 and Steap-3 
show significantly more activity than the control (*, p < 0.05, Student’s t test) and 
both Δ2-9 and ΔNAC showed significantly less activity than wild-type α-syn. 
B The levels of dopamine were assessed in the same cell lines. The levels of 
dopamine were measured using an ELISA based commercial assay. Shown are 
the mean and s.e.m. for four experiments. There were no significant differences in 
dopamine levels for any of the cell lines. 
Figure 7 FR activity and DOPAL toxicity. 
The levels of toxicity of DOPAL to SH-SY5Y cell lines were determined using an 
MTT assay. Cell lines were plated at equivalent density in to 24 well plates and 
exposed to increasing concentrations of DOPAL in 10 L of methanol for 48 hours. 
The survival relative to a methanol treated control (10 L) was determined and 
graphed as a percentage. Shown are the mean and s.e.m. for 4-6 experiments 
were shown. A DOPAL was significantly more toxic to cell lines overexpressing α-
syn or Steap-3 than the pCDNA control at concentrations of 2 M and above (p < 
0.05, Student’s t test). B When compared to wild-type α-syn the mutants of α-syn 
(Δ2-9 and ΔNAC) show significantly less susceptibility to DOPAL toxicity at 2 M 
and above while β-syn showed less susceptibility at 10 M DOPAL and above. 
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Table 1 Dopamine metabolites in SH-SY5Y cell line 
SH-SY5Y cells stably transfected with the protein indicated. Level of DOPAC and 
HVA were detected by HPLC with electrochemical detection. Values obtained were 
related to the initial protein concentration of the starting sample. Shown are the mean 
and s.e. for 3-4 samples each. * indicates significant difference to the to the 
pCDNA.3.1 transfected control. 
Cell Line DOPAC 
(ng/mg protein) 
HVA 
 (ng/mg protein) 
pCDNA 130 ± 46 640 ± 87 
-syn 320 ± 67* 876 ± 77* 
-syn 116 ± 68 527 ± 81 
2-9 197 ± 45 712 ± 67 
NAC 142 ± 44 595 ± 54 
Steap-3 387 ± 81* 923 ± 102* 
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